SINGAPORE March 1st, 2022: CellResearch Corporation (CRC) has named former Mundipharma and Eirgen executive Olivia Sutton as its new Head of Projects.

- Sutton who has spent over 20 years in the Pharmaceutical industry joins the leadership team of Singapore-based CellResearch Corporation during a pivotal time in the development of their platform technology

- CellResearch nears the completion of USFDA Phase 1 Trial and looks to expand trials globally as well as develop pipeline assets.

- The early-stage company, has already achieved ILAP (Innovative Licensing and Access Pathway) designation in the UK and has recently been awarded SME designation in Europe by the European Medicines Agency.

CellResearch has named former Eirgen and Mundipharma executive as its new Head of Projects. One of Singapore’s leading biotechnology firms, CellResearch, specialises in the development of therapeutics leveraging the power of its patented technology: stem cells sourced from the umbilical cord lining. CellResearch owns the first cGMP approved cell lines derived from the umbilical cord lining.

CellResearch is developing a pipeline of drugs that target a range of diseases including: Parkinson’s, AMD, Diabetes and Lupus. Its first therapy: CorLiCyte® targets chronic wounds and is approaching the latter stages of a Phase 1 trial in the US (Identifier: CT04104451).

On joining CRC Olivia said, “I am delighted and proud to have this opportunity to join the team at CRC. The potential of umbilical stem cell technology is huge and the published data is extremely promising. I am looking forward to leading the development of the CRC platform and bringing new therapeutic options to patients as soon as possible.”

Olivia Sutton joins CRC in February 2022 as Head of Projects. Olivia has over 20 years of experience in the pharmaceutical industry in a range of project management roles. Olivia was previously Head Of PMO at Eirgen Pharma in Ireland supporting the development of a number of high potency value-added generic R&D developments for global markets, in addition to overseeing the technical transfer of products with a range of development partners.

Prior to Eirgen Olivia was Executive Director of Project Management at Mundipharma where she managed teams in the U.K., Singapore, China and Japan. Olivia is an experienced project leader and has a broad range of experience leading R&D developments from Phases I through to commercialisation and market access in a range of therapeutic indications including pain, respiratory, immunological disorders, addiction and BPH, for markets across the EU, US, Asia Pacific and LATAM regions.

During her time at Mundipharma she successfully led a number of co-developments with partner companies and academia and is highly experienced in leading virtual teams to success.

Previous to her time in project management Olivia worked in regulatory affairs with roles in industry and at the MHRA in London.

Gavin Tan, CEO of CellResearch said of the appointment: “We are very excited to have appointed Olivia as our Head of Projects, her many years of experience within the industry will help make sure we reach the ambitious developmental targets we have set for ourselves in the coming years and accelerate the delivery of important therapies to the people that need them as quickly as possible”

About CellResearch Corporation

CellResearch Corporation(CRC) was founded in Singapore in 2002.It’s original remit was to provide skin and scar cells to laboratories around the world for research. In 2004, CRC scientists isolated Epithelial and Mesenchymal Stem Cells from the Umbilical Cord Lining Membrane. This novel and significant discovery was put up for intellectual property protection, and CRC now holds a portfolio of patents surrounding this discovery.

The umbilical cord lining membrane is now known to be the richest source of stem cells in the body, and both epithelial and mesenchymal stem cells are being researched intensively with collaborators all around the world to exploit their potential for downstream medical therapy.

CRC’s first therapeutic asset: CorLiCyte® is indicated for the treatment of Chronic Diabetic foot ulcers. It is in the latter stages of a Phase 1 trial in the US in partnership with the University of Colorado Anschutz medical campus. This technology has recently been award ILAP designation by the UK Health authority (MHRA) as a potentially innovative medicine.

CRC has been able to leverage this knowledge to produce a ground breaking cosmeceutical line called CALECIM® which has anti-aging benefits when applied topically to the skin.

It is available online at: calecimprofessional.com and in the best aesthetic clinics around the world.

Enquiries should be directed to:
Xavier Simpson (Investor Relations)
E-mail: xaviersimpson@cellresearchcorp.com Telephone: +6588156139